HOME >> BIOLOGY >> NEWS
Clinical study reports findings of combination therapy with DOXIL

Bridgewater, NJ (May 8, 2003) Results from a new study evaluating the combination of DOXIL (doxorubicin HCl liposome injection), vincristine and a reduced-dose dexamethasone, known as DVd, in patients with multiple myeloma were published in the November 15, 2002 issue of the journal Cancer. The study examined the efficacy, safety and convenience of the DVd regimen. Vincristine, a cancer chemotherapeutic, and dexamethasone are often given in combination with other drugs.

The Phase II study, conducted at the Cleveland Clinic Myeloma Research Program of the Taussig Cancer Center, investigated the safety, tolerability and efficacy of the DVd combination regimen in 33 patients with newly-diagnosed multiple myeloma. In the study, patients received at least six cycles of the DVd regimen. During each cycle, patients were administered intravenous (IV) DOXIL (40 mg/m2) and vincristine (2 mg) on the first day, and oral or intravenous dexamethasone (40 mg/day) for four days. This treatment regimen was repeated every four weeks.

Eighty-eight percent (29 patients) responded to treatment with the DVd regimen. Of these patients, four (12%) achieved a complete response, defined as complete disappearance of myeloma protein from the serum and urine by immune fixation, a bone marrow biopsy demonstrating less than 3% plasma cells, the absence of monoclonal plasma cells by immune staining of the bone marrow on two occasions at least four weeks apart, and no evidence of progressive disease by any other parameters. Eighteen patients (55%) had a major response, defined as a 50 percent or greater decrease of myeloma protein from the serum and urine, while seven patients (21%) had a minor response, defined as a decrease in bone pain, an improvement of performance status by one grade, and a reduction in serum myeloma protein of 25 percent or greater. The median time to progression in the study was 23.1 months with two-year and three-year progression-free survival rat
'"/>


8-May-2003


Page: 1 2 3 4 5 6

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
9. Clinical trial shows timing of chemotherapy improves survival in breast cancer
10. Clinical services must catch up
11. Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2019)... ... August 20, 2019 , ... ... bioactive technologies for the spine, today announced the 510(K) clearance of its novel ... modification that is proven to improve osseointegration through superior hydrophilicity and optimized surface ...
(Date:8/19/2019)... ... August 19, 2019 , ... Since ... use of ultra-thin two dimensional slices which are placed on microscope slides, stained ... complex tissues and complicated features such as vasculature and thus researchers in the ...
(Date:8/15/2019)... , ... August 15, 2019 , ... ... Now what? As serialization mandates become increasingly complex, and aggregation becomes fully applied ... serialization software is the best long-term solution. , Until now, most regulations?including the ...
Breaking Biology News(10 mins):
(Date:8/6/2019)... ... August 06, 2019 , ... ... joined forces in launching the biweekly SDBN BUZZ podcast focused on connecting the ... podcast will also serve to promote the region and attract external employers, investors, ...
(Date:8/4/2019)... MINNEAPOLIS (PRWEB) , ... August 02, 2019 , ... Cirtec ... minimally invasive devices, today announced that it has begun construction on a 30,000 sq. ... about 15 miles from San Jose. , The facility, which is expected to ...
(Date:7/19/2019)... ... July 18, 2019 , ... ... investment to enlarge their current piezo motion facilities in Lederhose, Germany, increasing their ... for multilayer piezo ceramic assembly production in addition to general office space, a ...
(Date:7/17/2019)... ... July 16, 2019 , ... Quidel is the market leader ... Abbott, Roche and Siemens Healthineers and Response Biomedical also are among the top ... for Point-of-Care (POC) Diagnostics . , Quidel is a market leader in rapid ...
Breaking Biology Technology:
Cached News: